Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Agenus Inc. - Common Stock
(NQ:
AGEN
)
5.630
+0.630 (+12.60%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 4, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Agenus Inc. - Common Stock
< Previous
1
2
3
4
5
Next >
Agenus and Zydus Lifesciences Enter $141M Strategic Collaboration to Advance BOT/BAL, Expand Zydus’ Biologics Manufacturing in the US
June 03, 2025
From
Agenus Inc.
Via
Business Wire
Agenus Presents New Data at ASCO Highlighting Botensilimab’s Immune Activation in MSS Colorectal Cancer
May 30, 2025
From
Agenus Inc.
Via
Business Wire
Agenus Announces New Data from Expanded MSS Metastatic Colorectal Cancer Cohort to be Presented at ESMO GI 2025
May 15, 2025
From
Agenus Inc.
Via
Business Wire
Agenus Reports Q1 2025 Financial Results and Key Business Updates
May 12, 2025
From
Agenus Inc.
Via
Business Wire
Renowned GI Oncology Leader Dr. Richard Goldberg Joins Agenus as Chief Development Officer
May 12, 2025
From
Agenus Inc.
Via
Business Wire
Agenus to Provide Corporate Update and First Quarter 2025 Financial Report
April 29, 2025
From
Agenus Inc.
Via
Business Wire
Agenus’ BOT/BAL Neoadjuvant Pan-Cancer Data from the NEOASIS Study Presented in an Oral Session at AACR
April 28, 2025
From
Agenus Inc.
Via
Business Wire
Agenus’ BOT/BAL Data in Pretreated Liver Cancer Presented at AACR 2025
April 25, 2025
From
Agenus Inc.
Via
Business Wire
Agenus Announces Botensilimab and Balstilimab Presentations at ASCO 2025
April 23, 2025
From
Agenus Inc.
Via
Business Wire
Agenus to Present New BOT/BAL Data in Two Presentations at AACR 2025
March 25, 2025
From
Agenus Inc.
Via
Business Wire
Agenus Unveils Colorectal Cancer Survey Findings, Highlighting the Urgent Need for Treatment Innovation
March 19, 2025
From
Agenus Inc.
Via
Business Wire
Agenus Reports Q4 and Year-End 2024 Results; Strategic Operational Improvements and Significant Cost Reductions Enhance Sustainability of Promising BOT/BAL Program
March 11, 2025
From
Agenus Inc.
Via
Business Wire
Agenus Reports Impact of Key Immuno-Oncology Data Presented at Leading Medical Conferences and Peer-Reviewed Publications
February 26, 2025
From
Agenus Inc.
Via
Business Wire
Agenus to Participate in B. Riley Securities Precision Oncology & Radiopharma Investor Conference
February 25, 2025
From
Agenus Inc.
Via
Business Wire
Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report
February 25, 2025
From
Agenus Inc.
Via
Business Wire
Agenus Presents New Botensilimab/Balstilimab Data in Gastric Cancer at AACR IO Annual Meeting
February 24, 2025
From
Agenus Inc.
Via
Business Wire
CORRECTING and REPLACING Agenus’ BOT/BAL Selected for Two Presentations at Upcoming AACR IO Annual Meeting
February 23, 2025
From
Agenus Inc.
Via
Business Wire
Agenus Announces Publication in the Journal of Clinical Oncology Highlighting Data from Botensilimab Plus Balstilimab in Relapsed/Refractory Metastatic Sarcomas
January 29, 2025
From
Agenus Inc.
Via
Business Wire
Agenus Presents Data at ASCO GI Demonstrating Impact of BOT/BAL in Colorectal Cancer Across Neoadjuvant and Advanced Disease
January 22, 2025
From
Agenus Inc.
Via
Business Wire
Agenus Announces Five Presentations at ASCO GI Highlighting BOT/BAL Activity Across Colorectal and Gastric Cancers
December 18, 2024
From
Agenus Inc.
Via
Business Wire
Agenus Announces Strategic Realignment to Focus on Core Programs and Significantly Reduce Costs
December 05, 2024
From
Agenus Inc.
Via
Business Wire
Agenus Secures $22 Million Mortgage and Announces Strategic Operational Realignment
November 27, 2024
From
Agenus Inc.
Via
Business Wire
Agenus Reports Third Quarter 2024 Financial Results and Strategic Advancements in BOT/BAL Development
November 12, 2024
From
Agenus Inc.
Via
Business Wire
Agenus to Present Compelling Data on Botensilimab and AGEN1721 at SITC 2024
November 07, 2024
From
Agenus Inc.
Via
Business Wire
Agenus to Provide Third Quarter 2024 Financial Report and Corporate Update
November 05, 2024
From
Agenus Inc.
Via
Business Wire
DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors of Agenus to Contact Us to Have Their Losses Evaluated Today
November 02, 2024
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Agenus
October 30, 2024
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against GitLab, Allarity, ZoomInfo, and Agenus and Encourages Investors to Contact the Firm
October 29, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
AGENUS INC. (NASDAQ: AGEN) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Agenus Inc. Investors of Upcoming Deadline
October 28, 2024
From
Bernstein Liebhard LLP
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Allarity, Metagenomi, Agenus, and New Fortress and Encourages Investors to Contact the Firm
October 22, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
< Previous
1
2
3
4
5
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.